EGFR and nonpapillary renal cell carcinoma: Due to the central role of the ERBB family in the tumorigenesis of solid tumors [23], afatinib is now in a phase II clinical trial (https://classic.clinicaltrials.gov/ct2/, NCT02465060) for the treatment of many solid tumors, including ccRCC.